Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Immuneering Corporation

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, SEPT. 26, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINICAL-STAGE ONCOLOGY COMPANY FOCUSED ON KEEPING CANCER PATIENTS ALIVE, TODAY ANNOUNCED THAT IT WILL HOST A CONFERENCE CALL AND LIVE WEBCAST AT 8:30 AM ET ON SEPTEMBER 29, 2025, TO DISCUSS RECENTLY ANNOUNCED UPDATED OVERALL SURVIVAL AND SAFETY DATA IN FIRST-LINE PANCREATIC CANCER PATIENTS TREATED WITH ATEBIMETINIB + MGNP (N=34) WITH 9 MONTHS MEDIAN FOLLOW UP.

IMMUNEERING TO DISCUSS RECENTLY ANNOUNCED OVERALL SURVIVAL DATA FROM PHASE 2A CLINICAL TRIAL OF ATEBIMETINIB + MGNP IN FIRST-LINE PANCREATIC CANCER PATIENTS ON MONDAY, SEPTEMBER 29, 2025

IMMUNEERING ANNOUNCES PRICING OF $175 MILLION UNDERWRITTEN PUBLIC OFFERING OF CLASS A COMMON STOCK AND CONCURRENT $25 MILLION PRIVATE PLACEMENT OF CLASS A

IMMUNEERING ANNOUNCES PRICING OF $175 MILLION UNDERWRITTEN PUBLIC OFFERING OF CLASS A COMMON STOCK AND CONCURRENT $25 MILLION PRIVATE PLACEMENT OF CLASS A COMMON STOCK TO SANOFI

IMMUNEERING ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF CLASS A COMMON STOCK AND PRE-FUNDED WARRANTS AND PROPOSED CONCURRENT PLACEMENT TO SANOFI

IMMUNEERING ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF CLASS A COMMON STOCK AND PRE-FUNDED WARRANTS AND PROPOSED CONCURRENT PRIVATE PLACEMENT OF CLASS A COMMON STOCK AND CLASS B COMMON STOCK TO SANOFI

- 86% OVERALL SURVIVAL (OS) OBSERVED AT 9 MONTHS; STANDARD OF CARE BENCHMARK IS ~47% - - 53% PROGRESSION-FREE SURVIVAL (PFS) OBSERVED AT 9 MONTHS; STANDARD OF CARE BENCHMARK IS ~29% - - COMPANY EXPECTS REGULATORY FEEDBACK ON PIVOTAL TRIAL PLANS IN Q4 2025 AND, SUBJECT TO THAT FEEDBACK, EXPECTS TO INITIATE PIVOTAL TRIAL BY THE END OF 2025 AND BEGIN DOSING PATIENTS BY MID-2026 - NEW YORK, SEPT. 24, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINICAL-STAGE ONCOLOGY COMPANY FOCUSED ON KEEPING CANCER PATIENTS ALIVE, TODAY ANNOUNCED POSITIVE UPDATED SURVIVAL AND SAFETY DATA FROM ITS ONGOING PHASE 2A TRIAL OF ATEBIMETINIB (IMM-1-104) IN COMBINATION WITH MODIFIED GEMCITABINE/NAB-PACLITAXEL (MGNP) IN FIRST-LINE PANCREATIC CANCER PATIENTS (N=34), WITH 9 MONTHS MEDIAN FOLLOW UP.

IMMUNEERING ANNOUNCES EXTRAORDINARY 86% OVERALL SURVIVAL AT 9 MONTHS IN FIRST-LINE PANCREATIC CANCER PATIENTS TREATED WITH ATEBIMETINIB + MGNP

NEW YORK, SEPT. 16, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINICAL-STAGE ONCOLOGY COMPANY FOCUSED ON KEEPING CANCER PATIENTS ALIVE, TODAY ANNOUNCED THE APPOINTMENT OF THOMAS J.

IMMUNEERING APPOINTS DR. THOMAS SCHALL AS CHAIRMAN OF THE BOARD

IMMUNEERING TO ANNOUNCE UPDATED OVERALL SURVIVAL DATA FROM PHASE 2A CLINICAL TRIAL OF ATEBIMETINIB + MGNP IN FIRST-LINE PANCREATIC CANCER PATIENTS ON SEPTE

IMMUNEERING TO ANNOUNCE UPDATED OVERALL SURVIVAL DATA FROM PHASE 2A CLINICAL TRIAL OF ATEBIMETINIB + MGNP IN FIRST-LINE PANCREATIC CANCER PATIENTS ON SEPTEMBER 25

CAMBRIDGE, MASS., AUG. 26, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINICAL-STAGE ONCOLOGY COMPANY FOCUSED ON KEEPING CANCER PATIENTS ALIVE, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED PRIVATE PLACEMENT.

IMMUNEERING ANNOUNCES CLOSING OF $25 MILLION PRIVATE PLACEMENT

- IMMUNEERING TO EVALUATE ATEBIMETINIB IN COMBINATION WITH OLOMORASIB IN PLANNED PHASE 2 TRIAL IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER  CAMBRIDGE, MASS., AUG. 25, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINICAL-STAGE ONCOLOGY COMPANY FOCUSED ON KEEPING CANCER PATIENTS ALIVE, TODAY ANNOUNCED A CLINICAL SUPPLY AGREEMENT WITH ELI LILLY AND COMPANY (NYSE:LLY) FOR ITS SECOND-GENERATION KRAS G12C INHIBITOR, OLOMORASIB (LY3537982).

IMMUNEERING ANNOUNCES CLINICAL SUPPLY AGREEMENT WITH LILLY TO EVALUATE ATEBIMETINIB IN COMBINATION WITH OLOMORASIB

CAMBRIDGE, MASS., AUG. 21, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINICAL-STAGE ONCOLOGY COMPANY FOCUSED ON KEEPING CANCER PATIENTS ALIVE, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A DEFINITIVE SECURITIES PURCHASE AGREEMENT FOR A PRIVATE PLACEMENT OF SECURITIES TO TOP-TIER INSTITUTIONAL AND OTHER ACCREDITED INVESTORS, THAT IS EXPECTED TO RESULT IN UP FRONT GROSS PROCEEDS TO THE COMPANY OF APPROXIMATELY $25 MILLION, BEFORE DEDUCTING FEES AND EXPENSES.

IMMUNEERING ANNOUNCES $25 MILLION PRIVATE PLACEMENT

- COMPANY NOW PLANS TO SHARE UPDATED OS AND PFS DATA FROM FIRST-LINE PANCREATIC CANCER PATIENTS (N = 34) TREATED WITH ATEBIMETINIB + MGNP IN Q3 2025, EARLIER THAN PRIOR GUIDANCE- - EXCEPTIONAL 94% OVERALL SURVIVAL (OS) OBSERVED AT 6 MONTHS IN ONGOING PHASE 2A TRIAL OF ATEBIMETINIB PLUS MODIFIED GEMCITABINE/NAB-PACLITAXEL (MGNP) IN FIRST-LINE PANCREATIC CANCER PATIENTS (N = 34)- - NEWLY ISSUED U.S. COMPOSITION OF MATTER PATENT FOR ATEBIMETINIB EXPECTED TO PROVIDE EXCLUSIVITY INTO 2042, WITH SUBSEQUENT OPPORTUNITY FOR PATENT TERM EXTENSION - - REQUEST FOR END OF PHASE 2 MEETING HAS BEEN SUBMITTED TO THE FDA; PIVOTAL TRIAL EXPECTED TO INITIATE IN 2026 - CAMBRIDGE, MASS., AUG. 13, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINICAL-STAGE ONCOLOGY COMPANY OUTPACING CANCER TO HELP PATIENTS OUTLIVE THEIR DISEASE, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED SEVERAL BUSINESS UPDATES.

Immuneering Corporation

IMRX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Immuneering Corporation

IMRX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

IMRX